期刊文献+

2562例他达拉非不良反应报告分析 被引量:2

Adverse Drug Reactions Induced by Tadalafil:Analysis of 2 562 Cases
下载PDF
导出
摘要 目的:比较和探讨他达拉非(希爱力)可疑不良反应发生的特点,旨在对临床规范用药提供有益借鉴。方法:查阅世界卫生组织药品不良反应数据库,检索并分析药品的不良反应报告。结果:药品不良反应报告主要集中在心血管、神经、消化等系统。严重不良反应如异常勃起的报告率逐年下降。结论:应该继续规范药物的临床应用,以尽量减少心肌梗死、异常勃起等严重不良反应的发生,对肺动脉高压、神经再生等病症的应用研究更应该谨慎进行。 OBJECTIVE: To compare and evaluate the characteristics of the suspected ADRs induced by Tadalafil in order to offer beneficial reference for clinical standard medication. METHODS: The ADR cases induced by Tadalafil collected from WHO ADR database were analyzed. RESULTS: The ADRs of Tadalafil mainly appeared in cardiovascular system, nervous system and digestive system. The reporting ratio of the serious ADR such as priapism decreased year by year. CONCLUSION : Continuing efforts should be paid to the standard use of Tadalafil in order to reduce the incidence of its serious ADRs such as myocardial infarction and priapism etc. The clinical trial on Tadalafil in the treatment of pulmonary hypertension and neurogenesis et al should be conducted with more caution.
出处 《中国医院用药评价与分析》 2009年第10期786-788,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
基金 国家自然科学基金资助项目(项目批准号30901492)
关键词 他达拉非 不良反应 分析 Tadalafil ADR Analysis
  • 相关文献

参考文献12

  • 1Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999[J] . BJU Int,2004, 93(6) :796.
  • 2Milman HA, Arnold SB. Neurologic, psychological, and aggressive disturbances with sildenafil [ J ]. Ann Pharmacother, 2002,36(7 - 8) : 1 129.
  • 3Jackson G, Gllies H, Osterloh I. Past, present, and future: a 7 - year update of Viagra- ( sildenafil citrate) [ J ].Int J Clin Pract, 2005,59(6) :680.
  • 4Tran D, Howes LG. Cardiovascular Safety of Sildenafil [ J]. Drug Sa, 2003;26 (7) :453.
  • 5Vitezic D. A Risk - Benefit Assessment of Sildenafil in the Treatment of Ereetile Dysfunction [ J ]. Drug Saf, 2001,24 (4) :255.
  • 6Cohen JS. Should Patients be Given an InitialLow Test Dose of Sildenafil [ J ] ? Drug Saf, 2000,23 ( 1 ) : 1.
  • 7Campbell HE. Clinical monograph for drug formulary review: erectile dysfunction agents[J]. Manag Care Pharm ,2005,11 (2) : 151.
  • 8Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors[J]. J Clin Pract ,2006,60( 8 ) :967.
  • 9王浩洋,黄宇烽.他达拉非治疗勃起功能障碍的安全性研究[J].中华男科学杂志,2007,13(8):762-764. 被引量:4
  • 10白文俊.他达拉非治疗ED的进展[J].中华男科学杂志,2007,13(6):568-572. 被引量:13

二级参考文献27

共引文献20

同被引文献19

  • 1李宏军.枸橼酸西地那非治疗抗抑郁剂引起的勃起功能障碍[J].中国男科学杂志,2006,20(3):70-70. 被引量:1
  • 2Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999[J]. BJUlnt,2004 ,93(6):796.
  • 3Milman HA, Arnold SB. Neurologic, psychological, and aggressive disturbances with sildenafil [ J ]. Ann Pharmacother, 2002,36 ( 7 - 8 ) : 1 129.
  • 4Jackson G, Gllies H, Osterloh I. Past, present, and future: a 7 - year update of Viagra ( sildenafil citrate) [ J ]. lnt J Clin Pract, 2005, 59 (6) : 680.
  • 5Tran D, Howes LG. Cardiovascular safety of sildenafil [J]. Drug Saf ,2003 ,26 (7): 453.
  • 6Vitezic D. A risk - benefit assessment of aildenafil in the treatment of erectile dysfunction [ J ]. Drug Saf, 2001,24 (4) : 255.
  • 7Cohen JS. Should patients be given an initialLow test dose of sildenafil[ J] ? Drug Saf, 2000,23 ( 1 ) : 1.
  • 8Campbell HE . Clinical monograph for drug formulary review: erectile dysfunction agents [ J ]. J Manag Care Pharm,2005,11 (2) :151.
  • 9Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors [ J ]. Int J Clin Pract, 2006, 60 (8) :967.
  • 10Kloner, RA. Cardiovascular effects of the 3 phosphodiesterase - 5 inhibitors approved for the treatment of erectile dysfunction [ J ]. Circulation, 2004, 110(19) :3 149.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部